Phosphatidylinositol 4-phosphate 5-kinase type 1 alpha (PIP5K1A) (PIP5K1A)

Phosphatidylinositol 4-phosphate 5-kinase type 1 alpha (PIP5K1A) is a lipid kinase that plays a critical role in the phosphoinositide signaling pathway by converting phosphatidylinositol 4-phosphate (PI4P) into phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) (UniProt: P48426). This product, PI(4,5)P2, serves as a secondary messenger and a precursor for other signaling molecules like IP3 and DAG, which are vital for calcium signaling and protein kinase C activation (PubMed: 24913155). PIP5K1A is frequently overexpressed in various malignancies, including prostate and breast cancers, where it promotes cell proliferation, survival, and migration by modulating the PI3K/Akt and androgen receptor signaling axes (PubMed: 24469055, PubMed: 25114043). Consequently, PIP5K1A has emerged as a promising therapeutic target, with small-molecule inhibitors like ISA-2011B demonstrating the ability to reduce tumor growth and induce apoptosis in preclinical models (PubMed: 24469055). Beyond its role in cancer, the enzyme is involved in regulating the actin cytoskeleton and endocytosis, making it a central hub for integrating extracellular signals with cellular structural changes (PubMed: 11500374). Its involvement in inflammatory responses further highlights its potential as a target for a range of pathological conditions (PubMed: 21822278).

Other names

PIP5K1-alphaPIP5KIalphaPhosphatidylinositol 4-phosphate 5-kinase type I alphaPIP5K1AType I alpha phosphatidylinositol 4-phosphate 5-kinase

Inhibition of PIP5K1A kinase activity, which reduces the production of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), thereby disrupting downstream oncogenic signaling pathways including PI3K/Akt and Androgen Receptor (AR) signaling (PubMed: 24469055, PubMed: 25114043).